Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lemborexant for REM sleep enhancement and fear extinction in PTSD
ACTRN12624001404516Phase 4Not yet recruiting
- Sponsor
- University of Melbourne
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in post-traumatic stress disorder (PTSD) comparing Lemborexant with Placebo (2 arms). Primary endpoints: Fear extinction recall, Rapid eye movement sleep and 1 more. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
lemborexant
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on ACTRN12624001404516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001404516.